09/08/2021 - 10:00 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company as of August 31, 2021

08/31/2021 - 7:30 am

DBV Technologies to Participate at Upcoming Investor Conferences

08/09/2021 - 10:30 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2021

08/06/2021 - 10:30 pm

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

08/02/2021 - 10:15 pm

DBV Technologies Reports Second Quarter 2021 Financial Results and Recent Business Developments

07/26/2021 - 10:30 pm

DBV Technologies to Report First Half 2021 Financial Results and Business Updates on August 2, 2021

07/07/2021 - 10:30 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2021

06/15/2021 - 10:30 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2021

06/02/2021 - 1:30 am

DBV Technologies to Present at Upcoming Investor Conferences

05/20/2021 - 10:52 pm | General Assembly

AGM 2021 – Quorum

05/19/2021 - 10:30 pm

DBV Technologies Announces Results of its 2021 Ordinary and Extraordinary General Meeting and the Appointment of Dr. Adora Ndu, Pharm.D., J.D., and Dr. Ravi Madduri Rao, M.D., Ph.D., as Members of its Board of Directors

05/17/2021 - 10:30 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2021

05/05/2021 - 11:00 pm

DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021

05/03/2021 - 7:30 am

DBV Technologies Reports Q1 2021 Financial Results

04/29/2021 - 7:30 am

DBV Technologies to Participate in Upcoming Investor Conferences

04/28/2021 - 10:30 pm

AGM 2021 – Total Number of Voting Rights and Existing Number of Shares

04/28/2021 - 7:30 am

Ordinary and Extraordinary General Meeting of May 19, 2021 to be Held in Closed Virtual Session Due to COVID-19 Pandemic

04/02/2021 - 10:30 pm

DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors

04/02/2021 - 12:30 am

Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021

03/26/2021 - 9:30 pm

DBV Technologies Announces a New Chair of its Audit Committee and Date of its Annual General Meeting

03/17/2021 - 11:30 pm

DBV Technologies Announces Filing of 2020 Annual Report on Form 10-K and 2020 Universal Registration Document

03/12/2021 - 10:30 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2021

03/11/2021 - 10:30 pm

DBV Technologies Reports Full-Year 2020 Financial Results and Recent Business Developments

03/05/2021 - 10:30 pm

DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference

03/04/2021 - 12:00 am

DBV Technologies Announces Date Change for Reporting Full Year 2020 Financial Results

03/01/2021 - 7:30 am

DBV Technologies to Report Full Year 2020 Financial Results on March 4, 2021

02/24/2021 - 7:30 am

DBV Technologies to Participate in Upcoming AAAAI 2021 Congress

02/22/2021 - 7:30 am

DBV Technologies Announces Appointment of Michele F. Robertson as Chief Legal Officer

02/19/2021 - 7:30 am

DBV Technologies to Participate in SVB Leerink Global Partners Healthcare Conference

02/11/2021 - 10:30 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2021

01/29/2021 - 10:30 pm

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

01/14/2021 - 10:30 pm

DBV Technologies Provides Update on Investigational Viaskin™ Peanut for Children Ages 4-11 Years

01/07/2021 - 7:30 am

DBV Technologies Announces Change in U.S. Reporting Status and Final Approval of Global Restructuring Process

01/05/2021 - 10:30 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2020

12/15/2020 - 10:30 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2020

11/24/2020 - 7:30 am

DBV Technologies Announces Leadership Changes

11/11/2020 - 4:30 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2020

11/10/2020 - 7:30 am

DBV Technologies to Highlight Data on Viaskin™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020

11/09/2020 - 7:30 am

DBV Technologies to Participate in Upcoming Investor Conferences

11/02/2020 - 7:30 am

DBV Technologies Announces Filing and Validation of Marketing Authorization Application for Viaskin™ Peanut by European Medicines Agency

10/30/2020 - 7:30 am

DBV Technologies Reports September 30, 2020 Cash Position

10/08/2020 - 10:01 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2020

09/15/2020 - 10:30 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company as of August 31, 2020

09/09/2020 - 7:30 am

DBV Technologies Announces Leadership Changes

09/02/2020 - 10:30 pm

DBV Technologies to Participate in Multiple September Investor Conferences

08/12/2020 - 10:01 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2020

08/04/2020 - 7:30 am

DBV Technologies Receives Complete Response Letter from FDA for Viaskin Peanut BLA in Children Ages 4-11 Years

07/31/2020 - 7:30 am | Finance

DBV Technologies Reports First Half 2020 Financial Results

07/20/2020 - 10:01 pm

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

07/15/2020 - 10:01 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2020

07/10/2020 - 3:03 pm

DBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut in The Journal of Allergy and Clinical Immunology

06/26/2020 - 8:30 am

DBV Technologies Provides Operational and Business Update

06/11/2020 - 10:01 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2020

06/04/2020 - 10:30 pm

DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital Congress 2020

06/02/2020 - 10:30 pm

DBV Technologies To Present at the Goldman Sachs 41st Annual Global Healthcare Conference

05/12/2020 - 10:01 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2020

04/30/2020 - 10:01 pm

DBV Technologies Reports March 31, 2020 Cash Position

04/20/2020 - 10:01 pm

DBV Technologies Announces Results of its 2020 Ordinary and Extraordinary General Meeting

04/15/2020 - 10:04 pm | General Assembly

Ordinary and Extraordinary General Meeting of April 20, 2020

04/15/2020 - 12:00 pm | Corporate

Monthly information regarding the total number of voting rights and total number of shares of the Company

04/10/2020 - 10:01 pm

Ordinary and Extraordinary General Meeting of April 20, 2020 to be Held in Closed Virtual Session Due to COVID-19 Pandemic

03/30/2020 - 10:01 pm | General Assembly

Ordinary and Extraordinary General Meeting of April 20, 2020

03/20/2020 - 9:15 pm

DBV Technologies Announces Filing of 2019 Universal Registration Document and 2019 Annual Report on Form 20-F

03/17/2020 - 9:00 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 29, 2020 and March 4, 2020

03/16/2020 - 9:30 pm

DBV Technologies Provides Update on Viaskin Peanut BLA for Children Ages 4-11 Years

03/16/2020 - 11:40 am | General Assembly

Monthly information regarding the total number of voting rights and total number of shares of the Company

03/04/2020 - 10:30 pm

DBV Technologies Reports Full-Year 2019 Financial Results and Provides Business Update

03/04/2020 - 10:01 pm

DBV Technologies Announces Closing of Underwriters’ Option to Purchase Additional Ordinary Shares in the Form of American Depositary Shares in Connection With its Global Offering

03/02/2020 - 7:30 am

DBV Technologies Announces Partial Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs)

02/24/2020 - 10:00 pm

DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020

02/21/2020 - 3:30 pm

DBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy in Children

02/10/2020 - 10:00 pm

DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference

02/07/2020 - 2:00 am

Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2020 and February 4, 2020

02/06/2020 - 10:01 pm

DBV Technologies Announces Appointment of Pascal Wotling as Chief Technical Operations Officer

02/04/2020 - 10:30 pm

DBV Technologies Announces Closing of Global Offering

01/30/2020 - 7:30 am

DBV Technologies Announces Pricing of $153.7 million (€139.8 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

01/29/2020 - 10:05 pm

DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports December 31, 2019 Cash Position

01/15/2020 - 10:00 pm

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

01/14/2020 - 10:00 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company

01/08/2020 - 10:30 pm

DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy

01/02/2020 - 10:30 pm

DBV Technologies Announces Appointment of Ramzi Benamar as Chief Financial Officer

12/10/2019 - 11:00 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company

11/19/2019 - 11:00 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company

11/05/2019 - 10:30 pm

DBV Technologies to Present at the Stifel 2019 Healthcare Conference

10/24/2019 - 10:01 pm

DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019

10/16/2019 - 12:30 pm | Corporate | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

10/15/2019 - 10:30 pm

DBV Technologies Announces Closing of Global Offering

10/10/2019 - 7:30 am

DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs)

10/09/2019 - 7:30 am

DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

10/08/2019 - 10:15 pm | Corporate

DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash Position

10/04/2019 - 5:45 pm

DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy

10/02/2019 - 10:00 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company

09/19/2019 - 10:00 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company

08/07/2019 - 10:05 pm

DBV Technologies Submits Biologics License Application to U.S. Food and Drug Administration for Viaskin Peanut for the Treatment of Peanut Allergy

08/01/2019 - 7:30 am | Finance

DBV Technologies Reports First Half 2019 Financial Results

07/18/2019 - 7:30 am

Amendment to the DBV Technologies Liquidity Contract with NATIXIS ODDO BHF and Half-Year Report

07/12/2019 - 12:00 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company

06/26/2019 - 7:30 am

DBV Technologies Announces Appointment of Pharis Mohideen, M.D., as Chief Medical Officer

06/11/2019 - 2:00 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company

06/03/2019 - 7:30 am

DBV Technologies to Attend Upcoming Investor Conferences

06/01/2019 - 2:00 pm

DBV Technologies to Present Data from Epicutaneous Immunotherapy at EAACI 2019

05/24/2019 - 10:30 pm

DBV Technologies Announces Results of its 2019 Ordinary and Extraordinary General Meeting and the Appointment of Viviane Monges to the Board of Directors

05/14/2019 - 7:30 am

DBV Technologies Announces Departure of Deputy CEO David Schilansky

05/03/2019 - 10:30 pm | General Assembly

Ordinary and Extraordinary General Meeting of May 24, 2019 Procedures for Obtaining Preparatory Documents for the General Meeting

05/02/2019 - 7:30 am | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

04/30/2019 - 7:30 am | Finance

DBV Technologies Reports March 31, 2019 Cash Position

04/10/2019 - 5:00 pm | Corporate

Information regarding the total number of voting rights and total number of shares of the Company

04/08/2019 - 10:30 pm | Finance

DBV Technologies Announces Closing of Global Offering

04/08/2019 - 5:00 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company

04/05/2019 - 7:30 am | Finance

DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares (ADS)

04/04/2019 - 8:00 am | Finance

DBV Technologies Announces Pricing of $70.4 million (€62.7 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

04/03/2019 - 10:10 pm | Corporate | Finance

DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares

04/01/2019 - 11:00 pm | Finance

DBV Technologies Announces Filing of 2018 “Document de Référence” and 2018 Annual Report on Form 20-F

03/06/2019 - 7:00 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company

03/05/2019 - 10:10 pm

DBV Technologies Reports Full Year 2018 Financial Results and Provides Operational Update

03/05/2019 - 7:30 am

DBV Technologies Announces Appointment of Michel de Rosen as Non-Executive Chairman of the Board of Directors

03/01/2019 - 7:30 am

DBV Technologies to Attend Upcoming Investor Conferences

02/22/2019 - 5:00 pm

DBV Technologies Announces Publication of Detailed Phase III Trial Results Evaluating Viaskin Peanut as a Novel Treatment for Peanut Allergy in The Journal of the American Medical Association

02/13/2019 - 10:07 pm

DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of Peanut-Allergic Children 4 to 11 Years of Age

02/08/2019 - 4:00 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company

02/04/2019 - 10:00 pm

DBV Technologies to Present Data on Epicutaneous Immunotherapy at AAAAI 2019

02/01/2019 - 7:30 am | Conferences

DBV Technologies to Present at the 8th Annual Leerink Partners Global Healthcare Conference

01/17/2019 - 7:30 am

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

01/11/2019 - 5:00 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company

01/03/2019 - 7:30 am

DBV Technologies Expands and Strengthens Leadership Team

12/19/2018 - 11:00 pm

DBV Technologies Provides Update on Viaskin Peanut for Children Four to 11 Years of Age

12/12/2018 - 7:30 am

DBV Technologies Highlights Data Supporting Induction of Immunotolerance Through the Skin at Inflammatory Skin Disease Summit 2018

12/06/2018 - 8:00 pm | Corporate | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

11/20/2018 - 7:30 am

DBV Technologies Presents Data at ACAAI 2018 on Investigational Viaskin Peanut for the Treatment of Peanut-Allergic Children

11/16/2018 - 7:30 am

DBV Technologies Appoints Daniel Tassé as Chief Executive Officer

11/09/2018 - 7:30 am

DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI Meeting

11/07/2018 - 6:30 pm | Corporate | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

10/30/2018 - 7:30 am | Finance

DBV Technologies Reports September 30, 2018 Cash Position

10/26/2018 - 7:30 am | Clinical

DBV Technologies Announces Initiation of Part B of Phase III Study in Peanut-Allergic Toddlers

10/22/2018 - 7:30 am | Corporate

DBV Technologies Announces Submission of Biologics License Application for Viaskin Peanut to the U.S. Food and Drug Administration

10/09/2018 - 5:00 pm | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

09/25/2018 - 7:30 am

DBV Technologies to Present at the Cantor Global Healthcare Conference

09/12/2018 - 7:30 am

DBV Technologies Announces Positive DSMB Review of Part A of Phase III Study in Peanut-Allergic Toddlers

09/07/2018 - 6:00 pm | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

09/07/2018 - 7:30 am | Finance

DBV Technologies Reports First Half 2018 Financial Results

09/05/2018 - 7:30 am | Science

DBV Technologies, Geneva University Hospitals and BioNet-Asia Presented Additional Phase I Data on the Use of an Investigational Epicutaneous Patch in Boosting Pertussis Vaccination at the European Congress of Immunology

08/31/2018 - 7:30 am

DBV Technologies to Attend Upcoming Investor Conferences

07/27/2018 - 7:30 am | Finance

DBV Technologies Reports June 30, 2018 Cash Position

07/26/2018 - 7:18 am

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

07/19/2018 - 12:30 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company

07/13/2018 - 7:30 am

Half-Year Report on the DBV Technologies Liquidity Contract and Transfer to Oddo BHF

06/26/2018 - 5:24 pm | Corporate

Monthly information regarding the total number of voting rights and total number of shares of the Company

06/22/2018 - 9:53 pm

DBV Technologies Announces Results of its 2018 Ordinary and Extraordinary General Meeting and the Appointment of Joan Schmidt as Executive Vice President, General Counsel

06/11/2018 - 5:00 pm | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

06/05/2018 - 7:30 am | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

06/01/2018 - 7:30 am | General Assembly

Annual General Meeting, June 22, 2018

Procedures for Obtaining Preparatory Documents for the General Meeting
Download PDF (461 KB)

05/29/2018 - 7:00 pm | General Assembly

Annual General Meeting, June 22, 2018

Information regarding the total number of voting rights and total number of shares of the Company on May 18th, 2018

Download PDF (256 KB)

05/29/2018 - 7:30 am | Medical Congresses

DBV Technologies Shows Commitment to the Development of Treatments for Food Allergies at EAACI 2018

05/16/2018 - 7:30 am | Corporate

DBV Technologies Announces Appointment of Michel de Rosen to its Board of Directors

05/14/2018 - 6:30 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company

05/14/2018 - 2:30 pm | Corporate

DBV Technologies Partners with FARE to Help Raise Awareness of Food Allergies in Support of the 21st Anniversary of Food Allergy Awareness Week

05/08/2018 - 7:30 am | Medical Congresses

DBV Technologies to Present New Clinical Data from Viaskin Platform at the 2018 EAACI Meeting

05/01/2018 - 7:30 am | Corporate

DBV Technologies to Attend Upcoming Investor Conferences

04/27/2018 - 7:30 am | Finance

DBV Technologies Reports March 31, 2018 Cash Position

04/05/2018 - 6:00 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company

04/03/2018 - 7:30 am | Conferences

DBV Technologies to Attend the 11th Kempen Life Sciences Conference

03/26/2018 - 10:00 pm | Finance

DBV Technologies Announces Closing of Underwriters’ Option to Purchase Additional Shares in Global Offering

03/23/2018 - 9:00 pm | Finance

DBV Technologies Announces Closing of Global Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

03/21/2018 - 8:14 am | Finance

DBV Technologies Announces Pricing of $150.0 million (€122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

03/20/2018 - 9:01 pm | Finance

DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares

03/16/2018 - 9:30 pm | Corporate | Finance

DBV Technologies Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F

03/14/2018 - 2:30 am | Finance

DBV Technologies Reports Full Year 2017 Financial Results

03/07/2018 - 1:30 am | Conferences

DBV Technologies to Present at the Barclays Global Healthcare Conference

02/28/2018 - 9:07 pm | Corporate

Monthly information regarding the total number of voting rights and total number of shares of the Company

02/26/2018 - 10:45 pm | Clinical

DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients

02/20/2018 - 7:30 am | Finance

DBV Technologies Reports December 31, 2017 Cash Position

02/14/2018 - 7:30 am | Clinical

DBV Technologies Provides Update on Regulatory Progress for Viaskin Peanut

02/13/2018 - 2:16 pm | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

02/12/2018 - 3:00 pm | Science

DBV Technologies to Highlight Viaskin Technology Platform at the 2018 AAAAI/WAO Joint Congress

02/01/2018 - 7:30 am | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

01/16/2018 - 7:30 am | Finance

Half-Year Report on the DBV Technologies Liquidity Contract with Natixis

01/12/2018 - 4:08 pm | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

01/03/2018 - 7:30 am | Conferences

DBV Technologies to Present at the 36th Annual J.P. Morgan Healthcare Conference

12/22/2017 - 12:30 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company

11/19/2017 - 8:49 pm

DBV Technologies Announces Positive Topline Safety Results from REALISE Phase III Trial of Viaskin Peanut for the Treatment of Peanut-Allergic Patients

10/20/2017 - 8:55 pm

DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut- Allergic Patients Four to 11 Years of Age

10/12/2017 - 8:48 pm

DBV Technologies Announces Completion of Blinded Period in REALISE Study of Viaskin Peanut

10/03/2017 - 5:58 pm | Corporate | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

09/05/2017 - 7:42 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company

09/01/2017 - 7:43 pm | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

08/29/2017 - 7:44 pm | Clinical

DBV Technologies Announces Completion of Enrollment in Phase III Extension Study of Viaskin Peanut

08/02/2017 - 7:57 pm | Clinical

DBV Technologies Initiates Phase III Study of Viaskin Peanut in Peanut-Allergic Patients One to Three Years of Age

07/28/2017 - 7:58 pm | Finance

DBV Technologies Reports First Half 2017 Financial Results

07/07/2017 - 8:00 pm | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

07/05/2017 - 8:01 pm | Finance

Half-Year Report on the DBV Technologies Liquidity Contract with Natixis

06/17/2017 - 8:32 pm | Science

DBV Technologies Highlights Poster Presentations on EPIT® at the 2017 EAACI Congress

06/15/2017 - 8:34 pm | General Assembly

DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting

06/12/2017 - 5:07 pm

DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting

06/01/2017 - 8:38 pm | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

05/12/2017 - 5:29 pm | Corporate | Finance

Ordinary and Extraordinary General Meeting of June 15, 2017 Procedures for Obtaining Preparatory Documents for the General Meeting

05/08/2017 - 9:27 pm | Science

DBV Technologies Highlights Research Presentation of EPIT® for the Treatment of Crohn’s Disease at Digestive Disease Week 2017

05/02/2017 - 5:32 pm | Conferences | Finance

DBV Technologies to Attend Upcoming Investor Conferences

04/28/2017 - 9:29 pm | Finance

DBV Technologies Reports March 31, 2017 Cash Position

04/05/2017 - 9:31 pm | Conferences

DBV Technologies to Attend the 10th Kempen Life Sciences Conference

04/05/2017 - 9:31 pm | Conferences

Monthly information regarding the total number of voting rights and total number of shares of the Company

03/30/2017 - 9:32 pm | Clinical | Corporate

DBV Technologies, BioNet-Asia and Geneva University Hospitals Announce Phase I Trial Results of Viaskin rPT in Pertussis Booster Vaccination

03/22/2017 - 11:30 pm | Corporate | Finance

DBV Technologies Announces Filing of its 2016 “Document de Référence” and Annual Report on Form 20-F

03/15/2017 - 7:30 am | Finance

DBV Technologies Reports Full Year 2016 Financial Results

03/10/2017 - 7:30 am | Clinical | Product Candidates

DBV Technologies Announces Completion of Enrollment of the REALISE Study in Peanut Allergic Children

03/07/2017 - 2:47 pm | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

03/05/2017 - 9:45 pm | Clinical | Conferences

Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic Children

03/01/2017 - 7:30 am | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

02/20/2017 - 7:30 am | Finance

DBV Technologies Reports December 31, 2016 Cash Position

02/10/2017 - 10:41 pm | Conferences | Corporate | Science

DBV to Present Data at the 2017 AAAAI Meeting Highlighting the Therapeutic Potential of EPIT®

02/05/2017 - 11:34 am | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

02/03/2017 - 7:30 am | Clinical | Product Candidates

DBV Technologies Announces Completion of Enrollment of Phase IIA Study of Viaskin Milk for the Treatment of Pediatric Eosinophilic Esophagitis

01/26/2017 - 7:30 am | Conferences

DBV Technologies to Present at the LEERINK Partners 6th Annual Global Healthcare Conference

01/09/2017 - 7:30 am | Corporate | Finance

DBV Technologies Announces Financial Calendar 2017

01/04/2017 - 5:38 pm | Finance

DBV Technologies Presents its Half-year Statement of the Liquidity Contract

01/04/2017 - 5:10 pm | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

12/07/2016 - 10:57 am | Corporate | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

11/17/2016 - 7:30 am | Clinical | Product Candidates

DBV Technologies, BioNet-Asia and Geneva University Hospitals Complete Dosing in First Cohort of Phase I Study of Viaskin rPT for Booster Vaccination Against Pertussis

11/16/2016 - 10:57 am | Corporate | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

11/12/2016 - 1:30 am | Science

DBV Technologies Announces Poster Presentations at the 2016 American College of Allergy, Asthma, and Immunology Meeting

11/10/2016 - 3:00 pm | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

11/08/2016 - 3:01 pm | Clinical | Product Candidates

DBV Technologies Completes Enrollment of Phase II Study of Viaskin Milk for the Treatment of Milk Allergic Patients

11/03/2016 - 3:03 pm | Finance

DBV Technologies Reports September 30, 2016 Cash Position

10/26/2016 - 3:04 pm | Clinical | Product Candidates

DBV Technologies Announces Publication of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study in the Journal of Allergy and Clinical Immunology

10/24/2016 - 3:05 pm | Clinical | Product Candidates

Topline Results from Two-Year Follow-Up Study of Viaskin Peanut Show Long-Lasting and High Levels of Desensitization to Peanut

10/17/2016 - 3:06 pm | Corporate | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

09/21/2016 - 3:07 pm | Product Candidates

DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cow’s Milk Protein Allergy

09/06/2016 - 3:08 pm | Clinical | Partnership

DBV Technologies, BioNet-Asia and the Geneva University Hospitals Initiate Phase I Study of Viaskin rPT for Pertussis Booster Vaccination

09/01/2016 - 3:09 pm | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

08/01/2016 - 3:10 pm | Clinical

DBV Technologies Announces Expansion of Clinical Program of Viaskin Peanut for the Treatment of Peanut Allergy

07/28/2016 - 7:30 am | Finance

DBV Technologies Reports Interim Financial Results for the First Half of 2016

07/11/2016 - 3:12 pm | Finance

Half year update on the DBV Technologies liquidity agreement

07/05/2016 - 3:13 pm | Corporate

DBV Technologies Proudly Welcomes Dr. Lucia Septién as Chief Medical Officer

06/27/2016 - 3:14 pm | Clinical

DBV Technologies Announces Completion of Recruitment in Global Phase III Study of Viaskin Peanut for the Treatment of Peanut Allergic Children

06/21/2016 - 8:31 pm | General Assembly

DBV Announced Results of its 2016 Annual Meeting of Shareholders

06/21/2016 - 3:15 pm | General Assembly

DBV Technologies Expands its Board of Directors with the Appointments of Claire Giraut and Maïlys Ferrere

06/16/2016 - 3:17 pm | Conferences

DBV Technologies to Present at the JMP Securities Life Sciences Conference

06/15/2016 - 3:17 pm | Product Candidates | Science

Late-Breaking Presentation at EAACI Highlights Viaskin® Peanut Data Providing Biomarker Insights for Monitoring Treatment Progression

06/13/2016 - 3:18 pm | Science

DBV Technologies Announces Publication of Preclinical Data in JACI Suggesting EPIT® Provides Sustained Protection Against Anaphylaxis

06/07/2016 - 3:19 pm | Corporate

DBV Technologies Announces Appointment of Leading Japanese Allergist, Dr. Motohiro Ebisawa, to its Scientific Advisory Board

06/01/2016 - 3:20 pm | Conferences | Science

DBV Technologies Data at EAACI 2016 Highlight Its Expansive Product Development in Food Allergies

05/31/2016 - 3:21 pm | Partnership

DBV Technologies and Nestlé Health Science Form Collaboration to Develop and Commercialize a Novel Diagnostic Test for Pediatric Milk Allergy

05/30/2016 - 8:30 pm | General Assembly

Mixed General Assembly of June 21, 2016 Procedures for obtaining preparatory documents for the Assembly

05/20/2016 - 3:23 pm | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

04/29/2016 - 3:24 pm | Finance

DBV Technologies Reports March 31, 2016 Cash Position

04/28/2016 - 3:25 pm | Corporate

DBV Technologies Announces Filing of 2015 “Document de Référence” and 2015 Annual Report on Form 20-F

04/27/2016 - 3:26 pm | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

04/11/2016 - 3:27 pm | Science

DBV Technologies Announces Publication of Experimental Data on Targeted Regulatory T Cell Induction during Epicutaneous Immunotherapy

04/07/2016 - 3:28 pm | Finance

DBV Technologies Reports Full Year 2015 Financial Results

03/06/2016 - 3:29 pm | Product Candidates

Additional Phase IIb Trial Results with Viaskin Peanut Presented at the 2016 AAAAI Meeting Continue to Support Treatment Safety, Efficacy and Compliance

03/04/2016 - 3:30 pm | Product Candidates

DBV Technologies Announces Presentation from NIAID-sponsored CoFAR6 Phase II Trial Reaffirming Viaskin® Peanut Safety and Efficacy

03/01/2016 - 3:31 pm | Conferences

DBV Technologies to Attend Upcoming Investor Conferences and Events

02/25/2016 - 3:32 pm | Product Candidates

DBV Technologies Announces Publication of Phase Ib Trial Results in the Journal of Allergy and Clinical Immunology (JACI) Supporting Safety and Tolerability of Viaskin® Peanut

02/15/2016 - 3:33 pm | Finance

DBV Technologies Reports December 31, 2015, Cash Position

02/10/2016 - 3:34 pm | Conferences | Finance

DBV Technologies to Present New Data at the 2016 AAAAI Annual Meeting

02/08/2016 - 3:35 pm | Conferences

DBV Technologies to Present at the LEERINK Partners 5th Annual Global Healthcare Conference

01/26/2016 - 3:36 pm | Corporate

DBV Technologies Proudly Welcomes Edward Jordan as Senior Vice President Commercial Operations North America

01/08/2016 - 3:38 pm

DBV Technologies Presents its Half-year Statement of the Liquidity Contract

01/08/2016 - 3:37 pm | Finance

DBV Technologies Announces 2016 Financial Calendar

01/07/2016 - 3:39 pm | Finance

DBV Technologies Presents its Half-year Statement of the Liquidity Contract

12/10/2015 - 6:29 pm | Science

First Experimental Results for the Treatment of Colitis with Viaskin® will be presented at the Crohn’s & Colitis Foundation of America’s 2015 Advances in IBD Conference (AIBD)

12/07/2015 - 7:00 pm | Clinical | Product Candidates

DBV Technologies Announces Initiation of Phase III Study of Viaskin® Peanut for the Treatment of Peanut Allergic Children

11/18/2015 - 7:01 pm | Clinical | Science

DBV Technologies to Present Preclinical Data on its Viaskin® Technology for RSV Vaccination at the 2015 RSV Vaccines for the World Meeting

11/12/2015 - 7:02 pm | Clinical

DBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis

11/03/2015 - 7:04 pm | Corporate | Finance

DBV Technologies Reports Interim Financial Results for the third quarter of 2015

10/22/2015 - 7:05 pm | Corporate

DBV Technologies Announces the Appointment of Michael J. Goller to its Board of Directors

10/14/2015 - 7:07 pm | Clinical | Product Candidates

DBV Technologies Announces First Patient Enrolled in Phase II Study of Viaskin Milk

10/05/2015 - 7:08 pm | Clinical | Product Candidates

Follow-Up Study of Viaskin® Peanut Shows Significant Increase in Peanut Consumption and Treatment Benefit in Peanut Allergic Children

09/11/2015 - 7:09 pm | Corporate | Finance

DBV Technologies To Enter SBF 120 Index

09/08/2015 - 7:10 pm | Conferences

DBV Technologies Invited to Present at the Royal Society of Medicine 11th Medical Innovations Summit

09/03/2015 - 7:11 pm | Conferences | Corporate

DBV Technologies to Attend Upcoming Investor Conferences and Events

08/31/2015 - 7:12 pm | General Assembly

DBV Technologies’ Extraordinary General Assembly on September 21, 2015

08/26/2015 - 10:17 pm | Conferences | Finance

DBV Technologies to Attend the Goldman Sachs European Biotech Symposium

07/28/2015 - 10:18 pm | Corporate | Finance

DBV Technologies Reports Financial Results   for the First Six Months of 2014  

07/27/2015 - 7:13 pm | Corporate | Finance

DBV Technologies Reports Interim Financial Results for the First Half of 2015

07/20/2015 - 7:14 pm | Finance

DBV Technologies Announces Closing of $281.5 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

07/17/2015 - 10:19 pm | Clinical | Product Candidates

DBV Technologies Completes last “food challenge” visit of last PeanutAllergic patient in VIPES Phase IIb Clinical Study

07/15/2015 - 7:15 pm | Corporate | Finance

DBV Technologies Announces Pricing of Underwritten Public Offering of Ordinary Shares

07/14/2015 - 7:16 pm | Corporate | Finance

DBV Technologies Announces Launch of Proposed Underwritten Public Offering of Ordinary Shares

07/08/2015 - 7:17 pm | Science

IND Acceptance from FDA for a proof-ofconcept trial using Viaskin® Milk in MilkInduced Eosinophilic Esophagitis in Children

07/02/2015 - 11:30 pm | Corporate | Finance

DBV Technologies announces the filing of a registration statement on Form F-1 in view of an offering of new shares in the form of American Depositary Shares, as well as the filing of its Reference Document

07/02/2015 - 6:30 pm | Corporate | Finance

Half year update on the DBV Technologies liquidity agreement

06/30/2015 - 7:20 pm | Corporate

DBV Technologies Announces Completion of Part A of the MILES Study Evaluating the Safety of Viaskin® Milk in Pediatric Cow’s Milk Allergy

06/26/2015 - 7:21 pm | Corporate

DBV Technologies Proudly Welcomes Dr. Hugh Sampson as Chief Scientific Officer

06/23/2015 - 11:00 am | Corporate

DBV Technologies’ June 23, 2015 Combined Shareholders’ Meeting

06/23/2015 - 12:00 am | Corporate

DBV Technologies Confirms Planned Initiation of Viaskin® Peanut Global Phase III Clinical Trial in Children Following Endof-Phase II Meeting with FDA and PIP approval by EMA

06/10/2015 - 7:24 pm | Science

Key Scientific Data Demonstrating that Epicutaneous Administration May Reactivate Protective Immunity against Pertussis in an experimental model published in Vaccine

06/08/2015 - 7:25 pm | Conferences | Science

DBV Technologies Presents Clinical and Scientific Data at the EAACI Congress

06/04/2015 - 7:27 pm | Corporate | Science

DBV Technologies Announces EMA Paediatric Committee (PDCO) positive opinion on the Paediatric Investigation Plan for Viaskin® Peanut for the Treatment of Peanut Allergic Children

06/02/2015 - 7:28 pm | Conferences | Finance

DBV Technologies to Attend Upcoming Investor Conferences

05/20/2015 - 11:30 am | Corporate

Publication of the Resolutions Proposed to the Mixed General Assembly of DBV

05/05/2015 - 7:31 pm | Conferences | Corporate | Finance

DBV Technologies to Present at Upcoming Investor Conferences

04/30/2015 - 7:32 pm | Corporate | Finance

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

04/29/2015 - 7:34 pm | Corporate | Finance

Topline Financial Results for First Three Months of 2015

04/28/2015 - 7:47 pm | Corporate | Finance

DBV Technologies Selected to Enter Euronext’s Tech 40 Label

04/15/2015 - 7:49 pm | Conferences | Corporate | Science

DBV Technologies to Present Viaskin® Data at the 2015 EAACI Congress

04/09/2015 - 7:50 pm | Corporate | Product Candidates

DBV Technologies Receives FDA Breakthrough Therapy Designation for Viaskin Peanut for the Treatment of Peanut Allergy in Children

03/25/2015 - 7:51 pm | Corporate | Finance

DBV Technologies Reports Full Year 2014 Financial Results

03/10/2015 - 7:52 pm | Corporate

DBV Technologies Appoints Daniel Soland to Board of Directors

03/06/2015 - 7:53 pm | Conferences | Finance

DBV Technologies to Present at Upcoming Investor Conferences

02/24/2015 - 7:54 pm | Conferences | Science

Viaskin® Data Presented at AAAAI Meeting Show Safety and Efficacy in the Treatment of Food Allergies

02/13/2015 - 7:56 pm | Corporate | Science

DBV Technologies Welcomes Dr. J-P Moreau to its Scientific Advisory Board

02/03/2015 - 7:57 pm | Conferences | Finance

DBV Technologies to Present at the 2015 Leerink Partners Global Healthcare Conference in New-York (USA)

02/03/2015 - 6:30 pm | Conferences | Science

Largest Presence Ever of DBV Technologies at 2015 Allergy Meeting

01/29/2015 - 7:30 am | Corporate | Finance

DBV Technologies Announces Topline Financial Results   for Full Year 2014  

01/14/2015 - 6:00 pm | Corporate | Finance

Half year update on the DBV Technologies liquidity agreement

01/12/2015 - 7:30 am | Science

DBV Technologies Announces Publication in the Journal of Allergy and Clinical Immunology of Data Demonstrating that Epicutaneous Immunotherapy may Influence the Natural History of Allergy

01/08/2015 - 7:30 am | Corporate

DBV Technologies Provides Organizational Update

11/20/2014 - 10:09 pm | Clinical | Product Candidates

DBV Technologies Initiates Phase I/II Clinical Trial with Viaskin Milk for the Treatment of Children with Cow’s Milk Allergy

10/23/2014 - 10:10 pm | Corporate | Finance

Global offering of DBV Technologies ordinary shares

Over-allotment option exercised in full
Download PDF (110 KB)

10/22/2014 - 10:11 pm | Corporate | Finance

DBV Technologies S.A. Announces Pricing of Global Offering

10/20/2014 - 10:13 pm | Corporate | Finance

DBV Technologies S.A. Announces Proposed Global Offering

10/14/2014 - 10:14 pm | Conferences | Finance

DBV Technologies Announces Topline Financial Results for First Nine Months 2014

09/22/2014 - 10:15 pm | Clinical | Science

DBV Technologies Announces Primary Endpoint Met in VIPES, Viaskin Peanut’s Phase IIb Clinical Trial in Peanut Allergy

07/17/2014 - 10:20 pm | Clinical | Partnership | Product Candidates

Consortium of Food Allergy Research Completes Recruitment of NIH-sponsored CoFar6 Phase II Trial with DBV’s Viaskin® Peanut in Treatment of Peanut Allergy

06/16/2014 - 10:21 pm | Corporate | Finance

DBV Technologies to Present at Upcoming US Investors Conferences

06/10/2014 - 11:35 pm | Conferences | Science

Five Scientific Communications at the European Academy of Allergy and Clinical Immunology Congress Further Support DBV’s EPITTM Disease Modifying Effect

05/13/2014 - 11:40 pm | Clinical | Partnership | Product Candidates

DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children

05/12/2014 - 11:43 pm | Corporate | Finance

DBV Technologies to Host and Webcast Investor Day in New York City on May 21, 2014

04/17/2014 - 11:44 pm | Corporate | Finance

DBV Technologies publishes its 2013 Registration Document and its 2013 Annual Financial Report

04/16/2014 - 11:45 pm | Clinical | Conferences | Product Candidates

DBV Announces the First reported case of a long term sustained effect of Peanut desensitization after Epicutaneous Immunotherapy (EPITTM) with Viaskin® at the French Congress of Allergy

CFA 2014 - Clinical Abstract
Download PDF (142 KB)

04/16/2014 - 6:10 am | Clinical | Conferences | Product Candidates

CFA 2014 – Clinical Abstract

DBV Announces the First reported case of a long term sustained effect of Peanut desensitization after Epicutaneous Immunotherapy (EPIT) with Viaskin® at the French Congress of Allergy
Download PDF (142 KB)

04/15/2014 - 11:46 pm | Corporate | Finance

DBV Technologies Announces Topline Financial Results   for First Three Months 2014  

04/09/2014 - 11:48 pm | Corporate | Partnership | Science

DBV Technologies and CEA conclude a scientific cooperation to investigate epigenetic modulation in epicutaneous immunotherapy

04/07/2014 - 11:49 pm | Corporate

DBV Technologies Announces Creation of US Subsidiary and Appoints Ms. Susanna Mesa as Vice President of Finance, US Investor Relations & Strategy

03/25/2014 - 11:49 pm | Conferences | Science

DBV Announces Data Presentations for EPIT at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2014

03/17/2014 - 11:51 pm | Clinical | Corporate | Finance

DBV Technologies Reports Full Year 2013 Financial Results and Provides VIPES Update

03/04/2014 - 11:52 pm | Conferences | Science

Presentation and Publication of Research at AAAAI Demonstrates EPITTM’s Ability to rebalance the Immune System and Induce a Disease-Modifying Effect

02/18/2014 - 11:53 pm | Corporate | Partnership | Science

DBV Technologies and Mount Sinai Hospital Enter Research Collaboration for Crohn’s Disease

01/30/2014 - 11:54 pm | Corporate | Finance

DBV Technologies Reports Full Year 2013 Topline Financial Results

12/17/2013 - 3:25 pm | Clinical | Corporate | Product Candidates | Science

DBV provides 2013 year-end summary and news flow guidance for 2014

12/13/2013 - 3:26 pm | Clinical | Conferences | Product Candidates | Science

Dr. Hugh Sampson presents Epicutaneous Immunotherapy for Food Allergy at the World Allergy Organization Conference

11/26/2013 - 3:28 pm | Corporate | Partnership | Science

DBV Technologies Enters into Collaboration Agreement with BioNetAsia and University of Geneva on Whooping Cough Booster Vaccine

11/14/2013 - 3:29 pm | Corporate | Finance

DBV Technologies announces the completion of a €29.9m private placement with a majority placed with US investors

10/24/2013 - 3:30 pm | Clinical | Partnership | Product Candidates

NIH-sponsored Consortium of Food Allergy Research (CoFAR) starts a Phase II clinical study with DBV Technologies’ Viaskin® Peanut in the treatment of peanut allergy

10/22/2013 - 3:31 pm | Corporate | Partnership | Science

DBV Technologies Forms Research Collaboration with Inserm to Develop Viaskin® for Refractory Hemophilia A Disease

10/18/2013 - 3:34 pm | Clinical | Corporate | Partnership | Product Candidates | Science

Stallergenes and DBV Technologies Announce Respiratory Allergy Research and Development Collaboration for Birch Pollen

10/15/2013 - 3:35 pm | Clinical | Corporate | Finance

DBV Announces Topline Financial Results for First Nine Months 2013 and Provides Safety Update on Viaskin® Peanut

09/04/2013 - 3:36 pm | Clinical | Product Candidates

DBV Technologies initiates a long-term follow-up study of Viaskin Peanut

07/08/2013 - 3:37 pm | Clinical | Product Candidates

DBV Technologies completes enrollment of Phase IIb VIPES study, the first-ever global trial in desensitization to peanut allergy

06/28/2013 - 3:38 pm | Conferences | Science

DBV Technologies announces breakthrough Data Presentations at EAACI-WAO Congress

06/20/2013 - 3:39 pm | Clinical | Partnership | Product Candidates

Viaskin Peanut demonstrates strong efficacy trend in severely peanut-allergic children in 18-month results of ARACHILD pilot study

05/16/2013 - 3:40 pm | Clinical | Partnership | Product Candidates | Science

Stallergenes and DBV Technologies enter into partnership for the development of innovative treatment of respiratory allergies

05/07/2013 - 3:41 pm | Corporate | Partnership | Science

DBV Technologies and Mount Sinai Hospital enter into a Research Collaboration Agreement

04/25/2013 - 3:42 pm | Corporate | Finance

DBV Technologies publishes its 2012 Registration Document and its 2012 Annual Financial Report

03/05/2013 - 3:43 pm | Corporate | Finance | Partnership

DBV Technologies enters into a strategic manufacturing agreement with Sanofi

03/04/2013 - 3:44 pm | Corporate | Finance | Science

DBV Technologies reports Full Year 2012 financial results and provides R&D update

01/31/2013 - 3:45 pm | Clinical | Corporate | Finance | Science

DBV Technologies Reports Full Year 2012 Topline and Provides an Update on R&D Activities

01/15/2013 - 3:46 pm | Corporate | Partnership | Science

DBV Technologies and INRA receive funding to develop pediatric bronchiolitis (‘RSV’) vaccine: RSV-NanoViaSkin

12/18/2012 - 7:00 am

DBV Technologies’ 2013 Financial calendar

11/14/2012 - 5:20 pm | Clinical | Corporate | Product Candidates | Science

DBV Technologies launches its third Viaskin® program, a first for the treatment of House Dust Mites (HDM) allergy in young children

10/16/2012 - 9:46 am | Corporate | Science

DBV Technologies and Centre d’Immunologie de Marseille-Luminy (CIML) enter in a Collaboration Agreement

10/15/2012 - 4:00 pm | Corporate | Finance

First nine months topline and clinical and business highlights

08/02/2012 - 5:42 pm | Clinical | Corporate | Product Candidates

DBV Technologies initiates VIPES phase IIb clinical study, the first global trial ever in desensitization of peanut-allergic children and adults

07/26/2012 - 9:19 am | Clinical | Corporate | Science

Half Year 2012 results and R&D highlights: DBV Technologies on track

07/19/2012 - 5:30 pm | Corporate | Science

DBV Technologies welcomes Mr. Stef Koppelman as its new General Scientific Advisor

06/18/2012 - 11:15 am | Clinical | Conferences | Product Candidates

DBV Technologies presents detailed results of a clinical study showing that VIASKIN® is safe and well-tolerated by peanut-allergic patients at the EAACI congress

06/18/2012 - 11:07 am | Clinical | Product Candidates

Positive interim clinical data in peanut allergic children treated with VIASKIN PEANUT

05/31/2012 - 11:20 am | Corporate | Science

Professor Hugh Sampson joins Scientific Advisory Board of DBV Technologies

05/15/2012 - 10:53 am | Clinical | Finance | Science

First quarter 2012 topline, scientific activity and upcoming clinical data

05/10/2012 - 11:01 am | Corporate

DBV Technologies welcomes Charles Ruban as Chief Development Officer

03/28/2012 - 10:28 am | Corporate | Finance

Successful Initial Public Offering (IPO) for DBV Technologies

02/28/2012 - 9:32 am | Clinical | Product Candidates | Science

Viaskin Peanut receives FDA “Fast Track Designation”

01/31/2012 - 10:05 am | Corporate | Finance

DBV Technologies announces the filing of its “Document de Base” with the French Autorité des marchés financiers

12/06/2011 - 10:26 am | Corporate | Finance

DBV Technologies introduces its new Chief Financial Officer

09/21/2011 - 10:32 am | Corporate

DBV Technologies moves to Bagneux

06/08/2011 - 9:09 am | Clinical | Science

DBV Technologies VIASKIN® technology has been chosen to feature on the cover of the European Journal of Allergy and Clinical Immunology June 2011 issue in its timeline “100 years allergen specific immunotherapy.”

01/18/2011 - 10:47 am | Corporate | Science

DBV Technologies elects George Horner as non­ executive Chairman

01/08/2011 - 9:58 am | Corporate | Science

DBV Technologies is very proud to have been chosen to feature on the cover of the Journal of Allergy and Clinical Immunology January 2011 issue

01/05/2011 - 10:57 am | Corporate | Finance

DBV Technologies closes $25.5 (€19,4) million Series ‘C’ financing round

09/23/2010 - 9:52 am | Corporate | Finance | Product Candidates

DBV Technologies Granted US Patents for Allergen Delivery System VIASKIN®

09/01/2010 - 10:00 am | Clinical | Product Candidates

VIASKIN® PEANUT Selected for U.S. Consortium of Food Allergy Research’s Peanut Allergy Desensitization Trial

07/06/2010 - 10:02 am | Clinical | Product Candidates

DBV Technologies Receives IND Clearance From FDA to Begin Clinical Trial in Peanut Allergy

06/14/2010 - 10:05 am | Corporate | Science

DBV Technologies expands Scientific Advisory Board with appointment of leading US allergy specialists

12/18/2009 - 12:50 am | Corporate

DBV Technologies appoints Professor Robert Zeiger to its Scientific Advisory Board

10/19/2009 - 12:47 am | Corporate

DBV Technologies appoints Professors Gideon Lack and Philippe Eigenmann to its Scientific Advisory Board

04/15/2009 - 12:45 am | Corporate | Partnership

DBV Technologies signs strategic agreement with Assistance Publique-Hôpitaux de Paris (AP-HP) office of technology transfer and industrial partnerships

02/19/2009 - 12:40 am | Corporate

DBV Technologies expands its Board of Directors

01/22/2009 - 11:20 am | Corporate | Finance

DBV Technologies raises €6 million in Series B investment and secures new corporate investor

11/13/2007 - 11:23 am | Corporate | Science

DBV Technologies Strengthens Board of Directors and Scientific Advisory Board

01/23/2006 - 11:25 am | Corporate | Finance

Sofinnova and Apax Partners invest €12 million in DBV Technologies